Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 5/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29853147 | 1.00 | CFD (0.41) | CFDXDHHTTHSD17B10TBXAS1 | |
| SCHEMBL23218606 | 0.90 | CFD (0.40) | CFDHTTHSD17B10TBXAS1 | |
| SCHEMBL29853115 | 0.90 | CFD (0.40) | CFDHTTHSD17B10TBXAS1 | |
| SCHEMBL29852822 | 0.89 | CFD (0.39) | CFDTBXAS1 | |
| SCHEMBL23219250 | 0.89 | CFD (0.39) | CFDTBXAS1 | |
| SCHEMBL29121619 | 0.89 | CFD (0.42) | CFDXDHHTTHSD17B10TBXAS1 | |
| SCHEMBL23219087 | 0.85 | CFD (0.48) | CFDTBXAS1NOS3NOS1NOS2 | |
| SCHEMBL29852733 | 0.85 | CFD (0.48) | CFDTBXAS1NOS3NOS1NOS2 | |
| SCHEMBL29123213 | 0.81 | CFD (0.42) | CFDHTTHSD17B10TBXAS1 | |
| SCHEMBL29121917 | 0.81 | CFD (0.42) | CFDHTTHSD17B10TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114502168-A | Oral complement factor D inhibitors | 拜奥克里斯特制药公司 | 2022-05-13 | — | — | CN | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2021072198-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2021-04-15 | — | — | WO | disclosed |